EGFR inhibition for recurrent or metastatic HNSCC

Affiliations

¹ Hygeia Hospital, Athens, Greece; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: athanassios.argiris@gmail.com.

Comment

Athanassios Argiris. Lancet Oncol. 2015 May.

. 2015 May;16(5):488-9.

doi: 10.1016/S1470-2045(15)70178-6. Epub 2015 Apr 16.

¹ Hygeia Hospital, Athens, Greece; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: athanassios.argiris@gmail.com.

No abstract available

Comment on

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Machiels JP, et al. Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16. Lancet Oncol. 2015. PMID: 25892145 Clinical Trial.